IN2012DN02993A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02993A
IN2012DN02993A IN2993DEN2012A IN2012DN02993A IN 2012DN02993 A IN2012DN02993 A IN 2012DN02993A IN 2993DEN2012 A IN2993DEN2012 A IN 2993DEN2012A IN 2012DN02993 A IN2012DN02993 A IN 2012DN02993A
Authority
IN
India
Prior art keywords
ebv
provides
present
cell
tcr
Prior art date
Application number
Other languages
English (en)
Inventor
Stauss Hans
Xue Shao-An
Topp Max
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of IN2012DN02993A publication Critical patent/IN2012DN02993A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN2993DEN2012 2009-09-29 2010-09-28 IN2012DN02993A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0917090.3A GB0917090D0 (en) 2009-09-29 2009-09-29 T-cell receptor
PCT/GB2010/001821 WO2011039508A2 (en) 2009-09-29 2010-09-28 T-cell receptor

Publications (1)

Publication Number Publication Date
IN2012DN02993A true IN2012DN02993A (enExample) 2015-07-31

Family

ID=41350560

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2993DEN2012 IN2012DN02993A (enExample) 2009-09-29 2010-09-28

Country Status (10)

Country Link
US (1) US8889141B2 (enExample)
EP (1) EP2483294B1 (enExample)
JP (2) JP6180114B2 (enExample)
KR (1) KR101760277B1 (enExample)
CN (1) CN102695717B (enExample)
AU (1) AU2010302477B2 (enExample)
ES (1) ES2584541T3 (enExample)
GB (1) GB0917090D0 (enExample)
IN (1) IN2012DN02993A (enExample)
WO (1) WO2011039508A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120059581A (ko) 2009-08-24 2012-06-08 윌슨 울프 매뉴팩처링 다중 종양 항원 또는 다중 바이러스에 대해 특이성을 갖는 ｃｔｌ주의 생성
CA2832569A1 (en) 2011-04-08 2012-10-11 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
HUE053444T2 (hu) 2011-10-28 2021-06-28 Regeneron Pharma Genetikailag módosított T-sejt receptoros egerek
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
JP6081483B2 (ja) 2011-12-12 2017-02-15 セル・メディカ・リミテッド Ｔ細胞を増殖させるプロセス
EP2812431B1 (en) 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
CA2884366A1 (en) 2012-09-12 2014-03-20 International Institute Of Cancer Immunology, Inc. Antigen-specific helper t-cell receptor genes
CN110511960B (zh) 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
DK3149031T3 (da) * 2014-05-29 2020-03-16 Us Health Anti-human papillomavirus 16 e7 t-cellereceptorer
WO2015199618A1 (en) * 2014-06-24 2015-12-30 National University Of Singapore Epstein-barr virus lmp2 specific antibody and uses thereof
AU2015338984A1 (en) * 2014-10-31 2017-04-27 The Trustees Of The University Of Pennsylvania Methods and compositions for modified T cells
CN107001444B (zh) * 2014-12-17 2020-11-27 中国科学院广州生物医药与健康研究院 识别eb病毒短肽的t细胞受体
US10253062B2 (en) 2014-12-23 2019-04-09 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
RU2732628C2 (ru) 2015-04-06 2020-09-21 Регенерон Фармасьютикалз, Инк. Опосредованные гуманизированными т-клетками иммунные ответы у не относящихся к человеку животных
CN104830793A (zh) * 2015-05-05 2015-08-12 杨光华 基于lmp-1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途
EP3307319A4 (en) 2015-06-09 2019-05-22 Memorial Sloan Kettering Cancer Center T CELL RECEPTOR-SIMILAR ANTIBODIES SPECIFIC TO PEPTID OF THE LATENT EBV MEMBRANE PROTEIN 2A PRESENTED BY HUMAN HLA
KR101794304B1 (ko) 2015-09-01 2017-11-06 가톨릭대학교 산학협력단 Ｅｂｖ 항원 특이 ｔ―세포 수용체 및 이의 용도
IL298359B2 (en) 2015-09-18 2025-12-01 Baylor College Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
GB201520191D0 (en) * 2015-11-16 2015-12-30 Cancer Rec Tech Ltd T-cell receptor and uses thereof
US11464853B2 (en) 2016-02-26 2022-10-11 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
EP3515921B1 (de) * 2016-09-19 2021-10-27 Bayer CropScience Aktiengesellschaft Pyrazolo[1,5-a]pyridin- derivative und ihre verwendung als schädlingsbekämpfungsmittel
CN108218976B (zh) * 2016-12-09 2021-11-05 香雪生命科学技术（广东）有限公司 衍生自lmp1的肿瘤抗原短肽
KR102148866B1 (ko) 2017-08-10 2020-10-14 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
EP3773632A4 (en) 2018-04-06 2022-05-18 The Regents of The University of California METHODS OF TREATMENT OF EGFRVIII-EXPRESSING GLIOBLASTOMA
CA3095757A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
KR20210098940A (ko) 2018-11-27 2021-08-11 듀크 유니버시티 Ebv 관련 암의 치료를 위한 항-lmp2 tcr-t 세포 요법
CN113423724B (zh) * 2018-12-27 2023-11-24 深圳华大生命科学研究院 Ebv表位高亲和力t细胞受体
EP3786178A1 (en) 2019-08-30 2021-03-03 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for ebv-derived antigens
WO2021211455A1 (en) * 2020-04-13 2021-10-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against lmp2
WO2021243695A1 (en) * 2020-06-05 2021-12-09 Guangdong Tcrcure Biopharma Technology Co., Ltd. Tcr-t cell therapy targeting epstein-barr virus
EP3940075A1 (en) * 2020-07-17 2022-01-19 Istituto Nazionale Di Genetica Molecolare-INGM Inhibitors of line1 and uses thereof
US12376573B2 (en) 2021-03-31 2025-08-05 Regeneron Pharmaceuticals, Inc. Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoire
EP4091627A1 (en) 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
CN113773378B (zh) * 2021-10-14 2023-11-03 深圳大学总医院 T细胞受体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101182531B (zh) * 2007-11-09 2010-06-02 暨南大学 Eb病毒特异性tcr基因相关的重组质粒及构建抗ebv特异性ctl的方法

Also Published As

Publication number Publication date
JP2013505734A (ja) 2013-02-21
JP2016047064A (ja) 2016-04-07
CN102695717A (zh) 2012-09-26
WO2011039508A2 (en) 2011-04-07
AU2010302477A1 (en) 2012-04-19
JP6180114B2 (ja) 2017-08-16
US8889141B2 (en) 2014-11-18
CN102695717B (zh) 2016-08-10
GB0917090D0 (en) 2009-11-11
WO2011039508A3 (en) 2011-06-30
EP2483294A2 (en) 2012-08-08
AU2010302477B2 (en) 2017-01-19
ES2584541T3 (es) 2016-09-28
US20120244132A1 (en) 2012-09-27
KR20120074291A (ko) 2012-07-05
EP2483294B1 (en) 2016-07-13
KR101760277B1 (ko) 2017-07-21

Similar Documents

Publication Publication Date Title
WO2011039508A3 (en) T-cell receptor
ZA202006432B (en) T cell receptors
MX350126B (es) Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo.
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
PH12016500272A1 (en) T cell receptors
NZ600732A (en) Oxyntomodulin peptide analogue
NZ598356A (en) Antigenic tau peptides and uses thereof
HRP20240676T1 (hr) Proteini domena skele na bazi fibronektina koji vezuju miostatin
WO2013151672A3 (en) Modified polynucleotides for the production of oncology-related proteins and peptides
JP2017514522A5 (enExample)
NZ706884A (en) Fc gamma receptor iib variants
MX377650B (es) Vacuna y métodos para reducir una infección por campylobacter.
NZ705899A (en) Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof
NZ599590A (en) Factor involved in latent infection with herpesvirus, and use thereof
JP2013505734A5 (enExample)
NZ629309A (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
MX2009007261A (es) Vacuna de peptido foxp3.
NZ586074A (en) LCLRP peptides, constructs and uses thereof
Koh et al. Degradation-resistant protein domains limit host cell processing and immune detection of mycobacteria
MX2010005816A (es) Epítopos de péptido de stat3.
JP2015527074A5 (enExample)
NZ603611A (en) Insulin-like growth factor 1 receptor binding peptides
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
EA201390811A1 (ru) Пептиды tomm34 и содержащие их вакцины